Analysis of the functional polymorphism in the cytochrome P450 CYP2C8 gene rs11572080 with regard to colorectal cancer risk

Frontiers in Genetics

Volumn 3, Issue DEC, 2012, Pages

  Ladero, José M ^a,b   Agúndez, José A G ^c   Martínez, Carmen ^c   Amo, Gemma ^c   Ayuso, Pedro ^d   García Martín, Elena ^c  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c UNIVERSITY OF EXTREMADURA   (Spain)

^d Fundación Instituto Mediterraneo Para el   (Spain)

Author keywords

Biomarkers; Colorectal cancer risk; CYP2C8; Polymorphisms; Xenobiotic metabolizing enzymes

Indexed keywords

EID: 84876075667     PISSN: None     EISSN: 16648021     Source Type: Journal    
DOI: 10.3389/fgene.2012.00278     Document Type: Article

References (41)

1. Agundez, J. A. (2004). Cytochrome P450 gene polymorphism and cancer. Curr. Drug Metab. 5, 211-224.
2. Agundez, J. A. (2008). Polymorphisms of human N-acetyltransferases and cancer risk. Curr. Drug Metab. 9, 520-531.
3. Agundez, J. A., Garcia-Martin, E., and Martinez, C. (2009). Genetically based impairment in CYP2C8-and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a com-bination of pharmacogenomics and metabolomics required to improve personalized medicine? Expert Opin. Drug Metab. Toxicol. 5, 607-620.
4. Bergheim, I., Bode, C., and Parlesak, A. (2005a). Decreased expression of cytochrome P450 protein in non-malignant colonic tissue of patients with colonic adenoma. BMC Gas-troenterol. 5:34. doi:10.1186/1471-230X-5-34
5. Bergheim, I., Bode, C., and Par-lesak, A. (2005b). Distribution of cytochrome P450 2C, 2E1, 3A4, and 3A5 in human colon mucosa. BMC Clin. Pharmacol. 5:4. doi:10.1186/1472-6904-5-4
6. Bigler, J., Whitton, J., Lampe, J. W., Fos-dick, L., Bostick, R. M., and Potter, J. D. (2001). CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk. Cancer Res. 61, 3566-3569.
7. Bosetti, C., Rosato,V., Gallus, S., Cuzick, J., and La Vecchia, C. (2012). Aspirin and cancer risk:a quantitative review to 2011. Ann. Oncol. 23, 1403-1415
8. Chan, A. T., Tranah, G. J., Giovan-nucci, E. L., Hunter, D. J., and Fuchs, C. S. (2004). A prospective study of genetic polymorphisms in the cytochrome P-450 2C9 enzyme and the risk for distal colorectal ade-noma. Clin. Gastroenterol. Hepatol. 2, 704-712.
9. Chan, A. T., Zauber, A. G., Hsu, M., Breazna, A., Hunter, D. J., Rosenstein, R. B., et al. (2009). Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma. Gastroenterology 136, 2127-2136.
10. Cleary, S. P., Cotterchio, M., Shi, E., Gallinger, S., and Harper, P. (2010). Cigarette smoking, genetic variants in carcinogen-metabolizing enzymes, and colorectal cancer risk. Am. J. Epidemiol. 172, 1000-1014.
11. Cotterchio, M., Boucher, B. A., Manno, M., Gallinger, S., Okey, A. B., and Harper, P. A. (2008). Red meat intake, doneness, polymorphisms in genes that encode carcinogen-metabolizing enzymes, and colorec-tal cancer risk. Cancer Epidemiol. Biomarkers Prev. 17, 3098-3107.
12. Cross, J. T., Poole, E. M., and Ulrich, C. M. (2008). A review of gene-drug interactions for nonsteroidal anti-inflammatory drug use in pre-venting colorectal neoplasia. Phar-macogenomics J. 8, 237-247.
13. Daily, E. B., and Aquilante, C. L. (2009). Cytochrome P450 2C8 pharmacoge-netics: a review of clinical studies. Pharmacogenomics 10, 1489-1510.
14. Daly, A. K., Aithal, G. P., Leathart, J. B., Swainsbury, R. A., Dang, T. S., and Day, C. P. (2007). Genetic suscep-tibility to diclofenac-induced hepa-totoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 132, 272-281.
15. Garcia-Martin, E., Martinez, C., Ladero, J. M., and Agundez, J. A. (2006a). Interethnic and intraethnic vari-ability of CYP2C8 and CYP2C9 polymorphisms in healthy indi-viduals. Mol. Diagn. Ther. 10, 29-40.
16. Garcia-Martin, E., Pizarro, R. M., Mar-tinez, C., Gutierrez-Martin,Y., Perez, G., Jover, R., et al. (2006b). Acquired resistance to the anticancer drug paclitaxel is associated with induc-tion of cytochrome P450 2C8. Phar-macogenomics 7, 575-585.
17. Garcia-Martin, E., Martinez, C., Ladero, J. M., Gamito, F. J., and Agundez, J. A. (2001). High frequency of muta-tions related to impaired CYP2C9 metabolism in a Caucasian popu-lation. Eur. J. Clin. Pharmacol. 57, 47-49.
18. Garcia-Martin, E., Martinez, C., Tabares, B., Frias, J., and Agundez, J. A. (2004). Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. Clin. Pharmacol. Ther. 76, 119-127.
19. Hubner, R. A., Muir, K. R., Liu, J. F., Logan, R. F., Grainge, M., Armitage, N., et al. (2006). Genetic variants of UGT1A6 influence risk of colorectal adenoma recurrence. Clin. Cancer Res. 12, 6585-6589.
20. Jonsdottir, S. O., Ringsted, T., Nikolov, N. G., Dybdahl, M., Wedebye, E. B., and Niemela, J. R. (2012). Identi-fication of cytochrome P450 2D6 and 2C9 substrates and inhibitors by QSAR analysis. Bioorg. Med. Chem. 20, 2042-2053.
21. Kury, S., Buecher, B., Robiou-Du-Pont, S., Scoul, C., Sebille, V., Colman, H., et al. (2007). Combinations of cytochrome P450 gene poly-morphisms enhancing the risk for sporadic colorectal cancer related to red meat consumption. Can-cer Epidemiol. Biomarkers Prev. 16, 1460-1467.
22. Landi, S., Gemignani, F., Moreno, V., Gioia-Patricola, L., Chabrier, A., Guino, E., et al. (2005). A compre-hensive analysis of phase I and phase II metabolism gene polymorphisms and risk of colorectal cancer. Phar-macogenet. Genomics 15, 535-546.
23. Liao, L. H., Zhang, H., Lai, M. P., Lau, K. W., Lai, A. K., Zhang, J. H., et al. (2007). The association of CYP2C9 gene polymorphisms with colorec-tal carcinoma in Han Chinese. Clin. Chim. Acta 380, 191-196.
24. Martinez,C.,Blanco,G.,Garcia-Martin, E., and Agundez, J. A. (2006). Clini-cal pharmacogenomics for CYP2C8 and CYP2C9: general concepts and application to the use of NSAIDs. Farm. Hosp. 30, 240-248.
25. Martinez,C.,Garcia-Martin,E.,Alonso-Navarro, H., Jimenez-Jimenez, F. J., Benito-Leon, J., Garcia-Ferrer, I., et al. (2007). Changes at the CYP2C locus and disruption of CYP2C8/9 linkage disequilibrium in patients with essential tremor. Neuromolecu-lar Med. 9, 195-204.
26. Martinez, C., Garcia-Martin, E., Blanco, G., Gamito, F. J., Ladero, J. M., and Agundez, J. A. (2005). The effect of the cytochrome P450 CYP2C8 poly-morphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects. Br. J. Clin. Pharmacol. 59, 62-69.
27. Martinez, C., Garcia-Martin, E., Ladero, J. M., Sastre, J., Garcia-Gamito, F., Diaz-Rubio,M.,et al. (2001).Associ-ation of CYP2C9 genotypes leading to high enzyme activity and colorec-tal cancer risk. Carcinogenesis 22, 1323-1326.
28. Martinez,C.,Garcia-Martin,E.,Pizarro, R. M., Garcia-Gamito, F. J., and Agundez, J. A. (2002). Expression of paclitaxel-inactivating CYP3A activ-ity in human colorectal cancer: implications for drug therapy. Br. J. Cancer 87, 681-686.
29. McGreavey, L. E., Turner, F., Smith, G., Boylan, K., Timothy Bishop, D., For-man, D., et al. (2005). No evidence that polymorphisms in CYP2C8, CYP2C9, UGT1A6, PPARdelta and PPARgamma act as modifiers of the protective effect of regular NSAID use on the risk of colorectal carci-noma. Pharmacogenet. Genomics 15, 713-721.
30. Northwood, E. L., Elliott, F., Forman, D., Barrett, J. H., Wilkie, M. J., Carey, F. A., et al. (2010). Poly-morphisms in xenobiotic metabo-lizing enzymes and diet influence colorectal adenoma risk. Pharmaco-genet. Genomics 20, 315-326.
31. Pittman, A. M., Webb, E., Carvajal-Carmona, L., Howarth, K., Di Bernardo, M. C., Broderick, P., et al. (2008). Refinement of the basis and impact of common 11q23.1 varia-tion to the risk of developing col-orectal cancer. Hum. Mol. Genet. 17, 3720-3727.
32. Sachse, C., Smith, G., Wilkie, M. J., Barrett, J. H., Waxman, R., Sulli-van, F., et al. (2002). A pharmacoge-netic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer. Carcinogenesis 23, 1839-1849.
33. Samowitz, W. S., Wolff, R. K., Curtin, K., Sweeney, C., Ma, K. N., Ander-sen, K., et al. (2006). Interactions between CYP2C9 and UGT1A6 polymorphisms and nonsteroidal anti-inflammatory drugs in colorec-tal cancer prevention. Clin. Gas-troenterol. Hepatol. 4, 894-901.
34. Siemes, C., Eijgelsheim, M., Dieleman, J. P.,Van Schaik, R. H., Uitterlinden,A. G.,Van Duijn,C. M.,et al. (2009). No modification of the beneficial effect of NSAIDs on colorectal cancer by CYP2C9 genotype. Neth. J. Med. 67, 134-141.
35. Snyderwine, E. G., Turesky, R. J., Turteltaub, K. W., Davis, C. D., Sadrieh, N., Schut, H. A., et al. (1997). Metabolism of food-derived heterocyclic amines in nonhuman primates. Mutat. Res. 376, 203-210
36. Tang, W. (2003). The metabolism of diclofenac -enzymology and tox-icology perspectives. Curr. Drug Metab. 4, 319-329.
37. Tomlinson, I. P., Webb, E., Carvajal-Carmona,L.,Broderick,P.,Howarth, K., Pittman, A. M., et al. (2008). A genome-wide association study identifies colorectal cancer suscep-tibility loci on chromosomes 10p14 and 8q23.3. Nat. Genet. 40, 623-630
38. Totah, R. A., and Rettie, A. E. (2005). Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin. Pharmacol. Ther. 77, 341-352.
39. Tranah, G. J., Chan, A. T., Giovannucci, E., Ma, J., Fuchs, C., and Hunter, D. J. (2005). Epoxide hydrolase and CYP2C9 polymorphisms, cigarette smoking,and risk of colorectal carci-noma in the nurses'health study and the physicians' health study. Mol. Carcinog. 44, 21-30.
40. Ulrich, C. M., Bigler, J., and Potter, J. D. (2006). Non-steroidal anti-inflammatory drugs for cancer pre-vention: promise, perils and phar-macogenetics. Nat. Rev. Cancer 6, 130-140.
41. Yasar,U.,Lundgren,S.,Eliasson,E.,Ben-net, A., Wiman, B., De Faire, U., et al. (2002). Linkage between the CYP2C8 and CYP2C9 genetic poly-morphisms. Biochem. Biophys. Res. Commun. 299, 25-28.